Immatics N.V.

NasdaqCM:IMTX Stock Report

Market Cap: US$1.4b

Immatics Management

Management criteria checks 4/4

Immatics' CEO is Harpreet Singh, appointed in Jul 2019, has a tenure of 6.75 years. total yearly compensation is €2.83M, comprised of 18.9% salary and 81.1% bonuses, including company stock and options. directly owns 0.16% of the company’s shares, worth $2.29M. The average tenure of the management team and the board of directors is 5.8 years and 4.9 years respectively.

Key information

Harpreet Singh

Chief executive officer

€2.8m

Total compensation

CEO salary percentage18.86%
CEO tenure6.8yrs
CEO ownership0.2%
Management average tenure5.8yrs
Board average tenure4.9yrs

Recent management updates

Recent updates

Revenues Not Telling The Story For Immatics N.V. (NASDAQ:IMTX) After Shares Rise 28%

Dec 05
Revenues Not Telling The Story For Immatics N.V. (NASDAQ:IMTX) After Shares Rise 28%

Investors Don't See Light At End Of Immatics N.V.'s (NASDAQ:IMTX) Tunnel

Sep 19
Investors Don't See Light At End Of Immatics N.V.'s (NASDAQ:IMTX) Tunnel

We Think Immatics (NASDAQ:IMTX) Can Afford To Drive Business Growth

Jun 22
We Think Immatics (NASDAQ:IMTX) Can Afford To Drive Business Growth

Lacklustre Performance Is Driving Immatics N.V.'s (NASDAQ:IMTX) Low P/S

May 17
Lacklustre Performance Is Driving Immatics N.V.'s (NASDAQ:IMTX) Low P/S

Immatics N.V.: Trading Below Cash, But Not Without Reason

Mar 28

Revenues Working Against Immatics N.V.'s (NASDAQ:IMTX) Share Price

Jan 12
Revenues Working Against Immatics N.V.'s (NASDAQ:IMTX) Share Price

Immatics N.V.'s (NASDAQ:IMTX) Price Is Out Of Tune With Revenues

Sep 21
Immatics N.V.'s (NASDAQ:IMTX) Price Is Out Of Tune With Revenues

Immatics (NASDAQ:IMTX) Is In A Good Position To Deliver On Growth Plans

Jul 12
Immatics (NASDAQ:IMTX) Is In A Good Position To Deliver On Growth Plans

Pinning Down Immatics N.V.'s (NASDAQ:IMTX) P/S Is Difficult Right Now

May 03
Pinning Down Immatics N.V.'s (NASDAQ:IMTX) P/S Is Difficult Right Now

We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely

Sep 26
We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely

We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely

Jun 12
We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely

Immatics launches $110M stock offering

Oct 10

Cancer immunotherapy biotech Immatics up 18% on 4x normal volume

Jul 19

Here's Why We're Watching Immatics' (NASDAQ:IMTX) Cash Burn Situation

Jan 29
Here's Why We're Watching Immatics' (NASDAQ:IMTX) Cash Burn Situation

Analysts' Revenue Estimates For Immatics N.V. (NASDAQ:IMTX) Are Surging Higher

Dec 16
Analysts' Revenue Estimates For Immatics N.V. (NASDAQ:IMTX) Are Surging Higher

Immatics N.V. (NASDAQ:IMTX) Analysts Are Pretty Bullish On The Stock After Recent Results

Apr 01
Immatics N.V. (NASDAQ:IMTX) Analysts Are Pretty Bullish On The Stock After Recent Results

What Is The Ownership Structure Like For Immatics N.V. (NASDAQ:IMTX)?

Jan 18
What Is The Ownership Structure Like For Immatics N.V. (NASDAQ:IMTX)?

CEO Compensation Analysis

How has Harpreet Singh's remuneration changed compared to Immatics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025€3m€533k

-€196m

Sep 30 2025n/an/a

-€120m

Jun 30 2025n/an/a

-€75m

Mar 31 2025n/an/a

-€22m

Dec 31 2024€4m€512k

€15m

Sep 30 2024n/an/a

-€49m

Jun 30 2024n/an/a

-€74m

Mar 31 2024n/an/a

-€77m

Dec 31 2023€6m€488k

-€95m

Sep 30 2023n/an/a

-€84m

Jun 30 2023n/an/a

-€79m

Mar 31 2023n/an/a

-€68m

Dec 31 2022€7m€522k

€28m

Compensation vs Market: Harpreet's total compensation ($USD3.31M) is below average for companies of similar size in the US market ($USD5.30M).

Compensation vs Earnings: Harpreet's compensation has been consistent with company performance over the past year.

CEO

Harpreet Singh (50 yo)

6.8yrs
Tenure
€2,826,000
Compensation

Dr. Harpreet Singh, Ph D., has been Non-Executive Director of Immatics N.V. since July 1, 2021 and served as its Supervisory Director since 2021 until July 1, 2021. Dr. Singh serves as Chief Executive Offi...

Leadership Team

NamePositionTenureCompensationOwnership
Harpreet Singh
CEO, MD6.8yrs€2.83m0.16%
$ 2.3m
Venkat Ramanan
Chief Financial Officerless than a yearno datano data
Amie Krause
Chief People Officerless than a yearno datano data
Hans-Georg Rammensee
Co-Founder & Member of the Scientific Advisory Board26.3yrsno datano data
Toni Weinschenk
Co-Founder & Chief Innovation Officer26.3yrsno data0.30%
$ 4.2m
Steffen Walter
Chief Operations Officer3.1yrsno data0.0075%
$ 105.3k
Ephraim Hofsäß
Vice President of SEC Reporting & Accounting2.3yrsno datano data
Edward Sturchio
General Counsel & Secretary5.8yrsno data0.15%
$ 2.1m
Lauren Schroeder
Vice President of Marketing2.3yrsno datano data
Carsten Reinhardt
Chief Development Officer6.5yrsno data0.036%
$ 503.1k
Rainer Kramer
Chief Business Officer & Site Head Munichno datano data0.31%
$ 4.4m
Cedrik Britten
Chief Medical Officer5.8yrsno data0.00019%
$ 2.7k
5.8yrs
Average Tenure
53.5yo
Average Age

Experienced Management: IMTX's management team is seasoned and experienced (5.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Harpreet Singh
CEO, MD4.8yrs€2.83m0.16%
$ 2.3m
Hans-Georg Rammensee
Co-Founder & Member of the Scientific Advisory Boardno datano datano data
Michael Atieh
Independent Non-Executive Director4.8yrs€309.00k0.065%
$ 918.1k
Peter Chambré
Non-Executive Chairman4.8yrs€329.00k0.079%
$ 1.1m
Heather Mason
Independent Vice Chair of the Board of Directors4.8yrs€289.00k0.065%
$ 918.1k
Hidde L. Ploegh
Member of Scientific Advisory Board5.8yrsno datano data
Patrick Hwu
Co-Chair of the Scientific Advisory Board5.1yrsno datano data
Paul Carter
Independent Non-Executive Director4.8yrs€304.00k0.065%
$ 918.1k
Cassian Yee
Member of Scientific Advisory Boardno datano datano data
Gwendolyn Binder
Member of Scientific Advisory Board6.3yrsno datano data
Crystal Mackall
Co-Chair of the Scientific Advisory Board5.6yrsno datano data
Roland Kontermann
Member of Scientific Advisory Board5.8yrsno datano data
4.9yrs
Average Tenure
65yo
Average Age

Experienced Board: IMTX's board of directors are considered experienced (4.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/09 21:26
End of Day Share Price 2026/04/09 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Immatics N.V. is covered by 12 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alec StranahanBofA Global Research
Eric SchmidtCantor Fitzgerald & Co.
Yevgeniya LivshitsChardan Capital Markets, LLC